Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178943 · ClinicalTrials.gov registry record
Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
A clinical trial, sponsored by CareDx.
- Completed
- Registry status
- 100
- Enrollment target
NCT02178943: Completed study, sponsored by CareDx.
NCT02178943 is a clinical trial that has completed, run by CareDx. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02178943 has completed, sponsored by CareDx.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
Primary Outcome
Graft dysfunction, Rejection with hemodynamic compromise: Hemodynamic compromise is defined by the presence of one or more of the following criteria: Proportional decrease in LVEF ≥ 25%, Absolute LVEF ≤ 30%, Need for inotropic support, Cardiac index \< 2.0 L/min/m2, Death (re-transplantation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-06 |
| Est. Completion | 2020-02 |
What the finished NCT02178943 record still lists
NCT02178943 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02178943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02178943 about?
NCT02178943 is a clinical study titled "Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling". Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
What is the current status of trial NCT02178943?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2014-06. Estimated completion is 2020-02.
Who is sponsoring clinical trial NCT02178943?
This trial is sponsored by CareDx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia